
A committee that advises the Centers for Disease Control and Prevention on vaccines voted Thursday to recommend the use of a new preventative therapy for RSV in babies, Merck’s Enflonsia. The monoclonal antibody, given to babies under 8 months of age entering their first RSV season, is the second product of this kind to enter … [Read more…]